The accumulation of Liposomal Doxorubicin in tissues treated by radiofrequency ablation and irreversible electroporation in liver – in vivo experimental study on porcine models
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Purpose To compare the accumulation of liposomal doxorubicin in liver tissue treated by radiofrequency ablation (RFA) and irreversible electroporation (IRE) in in vivo porcine models. Material and methods A total of 16 RFA and 16 IRE procedures were performed in the healthy livers of 2 groups of 3 pigs. RFA parameters included: StarBurstXL needle, 100W, and target temperature 105 °C for 7 min. One-hundred 100 µsec IRE pulses were delivered using 2 monopolar electrodes at 2250V at 1Hz. In each group, two pigs were administered MYOCET, 50mg (0.5mg/kg), while one pig served as a control. Sample harvesting from the central and peripheral zones of the ablation zones occurred at 24 and 72 hours. Doxorubicin concentrations were analyzed using fluorescence spectrofluorimetry of homogenized tissue. Results RFA treatment zones created with concomitant administration of doxorubicin were significantly larger than bland controls (2.5±0.3cm vs. 2.2±0.2cm) (p<0.05). By contrast, IRE treatments zones were negatively influenced by chemotherapy (2.2±0.4cm vs. 2.6±0.4cm) (p<0.05). At 24 hours, doxorubicin concentrations were significantly increased in comparison to untreated parenchyma in the peripheral and central zones of RFA (0,431±0,078µg/g and 0.314±0.055µg/g vs. 0.18±0,012µg/g) (p<0.05). Doxorubicin concentrations in IRE zones were not significantly different from untreated liver (0.191±0.049µg/g and 0.210±0.049µg/g vs. 0.18±0.012µg/g). Significant decreases in doxorubicin concentration were noted for RFA zones after 72 hours (0.366±0.088µg/g vs 0,22±0.044µg/g). There was no difference in doxorubicin concentration from 24 to 72 hours in IRE zones. Conclusion We observed increased accumulation of periprocedural doxorubicin following RFA, but a contrary effect when combined with IRE. |
| Related projects: |